Lenacapavir's $28,000 PrEP Price Tag Threatens to Undercut Near-Perfect Efficacy With Access Failure

FDA's H1 2026 Approvals Dominated by Cancer, Rare Disease

The FDA approved 26 novel therapies in the first half of 2026, marking an increase of seven from H1 2025. Oncology and rare diseases were the leading therapeutic areas, with four novel cancer medicines and six orphan indications receiving greenlights. Overall, the agency issued 79 approvals, including supplemental nods. AstraZeneca and Johnson & Johnson were prominent, securing a combined 11 approvals during this period.

• The FDA greenlit a total of 79 approvals in the first half of 2026, which included 26 novel therapies. This represents a significant increase of seven novel drug approvals compared to the first half of 2025, indicating a period of regulatory productivity despite leadership instability and workforce attrition.
• Oncology led the way in overall approvals, followed by rare diseases and inflammatory and immunological (I&I) indications. Specifically, four new cancer medicines and six treatments for orphan indications were approved, highlighting the agency's focus on these critical therapeutic areas.
• AstraZeneca secured six FDA greenlights, including for its TROP2-directed antibody drug conjugate Datroway for first-line metastatic triple-negative breast cancer. Johnson & Johnson received five approvals, notably for Icotyde, a daily peptide pill for plaque psoriasis co-developed with Protagonist Therapeutics.
• The first half of 2026 saw notable advancements in the rare disease space, including the approval of Denali Therapeutics’ Avlayah as the first treatment for Hunter syndrome addressing neurological complications, and Regeneron’s gene therapy Otarmeni, the first treatment to target an underlying cause of deafness and Regeneron's first gene therapy to market.

H1 2026 FDA Approvals: Evolving the Cancer Treatment Landscape

Over the past five years, the oncology treatment landscape has undergone a fundamental shift from cytotoxic-dominant paradigms toward precision medicine, biomarker-driven therapy, and novel immunological approaches. Immune checkpoint inhibitors (ICIs) have expanded well beyond their initial indications, gaining approval in the metastatic setting and subsequently in earlier-stage disease — most notably with pembrolizumab in early-stage triple-negative breast cancer. Antibody-drug conjugates (ADCs) have similarly evolved from late-line rescue therapies into earlier lines of treatment, with HER2-directed agents leading the way and newer constructs targeting TROP-2, HER-3, and LIV-1 broadening the addressable patient population. In metastatic renal cell carcinoma, immune-based combinations — ICI plus ICI, or ICI plus antiangiogenic agents — have displaced prior standards of care with demonstrated survival superiority. Concurrently, investigator-initiated trial data from China reflect the broader global trajectory: cytotoxic drug therapy declined from 48.9% to 34.8% of cancer-related trials between 2010–2014 and 2015–2019, while immune cell therapy doubled from 4.5% to 9.6% and targeted therapy rose from 14.2% to 17.8% over the same period.

Precision medicine and genomic profiling have matured from exploratory tools into actionable clinical infrastructure. Comprehensive 523-gene panel profiling identified actionable alterations in 67% of tumors — more than double the yield of a 50-gene panel — and in studies with sufficient follow-up, 52% of patients received targeted therapy or immunotherapy versus 32% treated with conventional chemotherapy alone, with significantly improved overall survival in the targeted therapy cohort (P < 0.001). Basket trial data from 75 trials enrolling 7,659 patients (2001–2023) reported a pooled objective response rate of 18.0% (95% CI 14.8–21.1), a median progression-free survival of 3.1 months, and median overall survival of 8.9 months — outcomes that, while modest in aggregate, reflect the heterogeneity of tissue-agnostic populations and underscore the importance of biomarker stratification. Trial design itself has evolved in parallel, progressing from tissue-specific phase 1–3 studies through biomarker-driven and tissue-agnostic designs toward N-of-1 precision medicine frameworks, with artificial intelligence and machine learning increasingly recognized as necessary tools for navigating the combinatorial complexity of genomic-guided therapy selection.

Despite these advances, significant structural and equity-related gaps persist. An analysis of 794 phase 3 oncology trials from 2002–2020 found that only 3% assessed local therapies such as surgery or radiation, with systemic therapy trial growth substantially outpacing that of local therapy (slope 7.57 vs. 0.28 annually). Long-term survival data continue to show stark geographic and economic disparities: pooled 5-year net survival is projected at 63.9% in North America and 70.4% in Oceania by 2025, compared to 34.4% in Africa and 38.7% in Asia. Emerging modalities — including mRNA cancer vaccines, particularly for pancreatic ductal adenocarcinoma, and ctDNA-based minimal residual disease monitoring — represent the next frontier of clinical investigation, with randomized trials underway to define their impact on recurrence-free and overall survival. Metabolic targeting strategies, including glycolysis inhibitors in combination with immunotherapy, are also entering early clinical evaluation, reflecting the expanding mechanistic scope of oncology drug development.

Targeting Key Unmet Needs in Oncology with New Approvals

Recent oncology approvals have been shaped by a landscape of persistent therapeutic gaps — from late-stage diagnoses and treatment resistance to geographic disparities in access and outcomes. The populations most urgently targeted reflect both biological complexity and systemic inequities that continue to limit survival gains despite decades of therapeutic innovation.

• Treatment resistance across modalities remains the most pervasive unmet need, with a substantial proportion of patients failing to derive durable benefit from surgery, radiation, chemotherapy, targeted therapy, and immunotherapy — often experiencing relapses driven by chemoresistance and immune evasion mechanisms within the tumor microenvironment (TME), including hypoxia, metabolic reprogramming, and immune exclusion.

• Advanced and metastatic solid tumors represent a primary target population, specifically patients with unresectable head and neck squamous cell carcinoma, esophageal cancer, non-small cell lung cancer, hepatocellular carcinoma, bladder cancer, and gynecological malignancies (cervical, endometrial, and ovarian carcinoma), all of which carry poor prognoses and limited late-line options.

• Metastatic gastric cancer constitutes a critically underserved population: in the US, 35%–65% of patients present with metastatic disease at diagnosis, and fewer than 10% survive beyond 5 years, underscoring the need for novel first- and second-line strategies.

• Biomarker-unselected and immunotherapy-refractory patients — particularly those with triple-negative breast cancer (TNBC), which lacks the receptor targets driving the most effective regimens — represent a high-priority group, as robust predictive biomarkers for immune checkpoint blockade (ICB) response have not yet been established in this setting.

• Frail and elderly patients with advanced cancer face compounded challenges, as even modern agents with improved tolerability profiles can impose substantial toxicity burdens, limiting access to standard-of-care regimens and highlighting the need for treatment strategies optimized for this cohort.

• Low- and lower-middle-income countries (LMICs) exhibit profoundly disparate outcomes, with 5-year net survival rates of only 4.1% and 17.8%, respectively, compared to 59.0% in high-income countries — driven by late-stage presentation, limited genomic profiling infrastructure, and slow progress in cancer control, particularly across Sub-Saharan Africa and low-income Commonwealth member states.

• Escalating global incidence frames the urgency of these unmet needs: GLOBOCAN 2020 recorded 19.3 million new cases and approximately 10.0 million deaths, with projections reaching 28 million new cases and 16.2 million deaths annually by 2040 — a trajectory that current therapeutic paradigms are insufficient to meaningfully deflect.

Emerging Targets and Mechanisms Driving Oncology Approvals

Recent oncology research has expanded the landscape of actionable therapeutic targets well beyond established pathways, encompassing ubiquitin–proteasome regulators, RNA-binding proteins, immune-modulatory receptors, and radiopharmaceutical vectors. These emerging targets span multiple tumor types and mechanistic classes, reflecting a broader shift toward precision oncology and molecularly guided treatment strategies.

• SAG/RBX2/ROC2/RNF7 (Multiple Cancers): This dual E3 ligase is overexpressed across numerous human cancer types and positively correlates with poor patient survival. Acting as the catalytic subunit of CRL5 and CRL1, SAG ubiquitylates and degrades tumor suppressor substrates, promoting oncogenesis. SAG knockdown or knockout leads to tumor suppressor accumulation, inhibiting cancer cell growth and tumor progression. Small molecule inhibitors and PROTAC degraders are actively being pursued as therapeutic strategies.

• C5aR1 (Hepatocellular Carcinoma): Identified as a novel target of citalopram via drug repurposing approaches — including global reverse gene expression profiling, drug affinity responsive target stability assay, and molecular docking — C5aR1 is predominantly expressed by tumor-associated macrophages. Citalopram treatment enhances local macrophage phagocytosis and elicits CD8⁺ T cell anti-tumor immunity; notably, this anti-HCC effect is independent of citalopram's conventional serotonin transporter activity. C5aR1 deficiency or CD8⁺ T cell depletion abrogates these effects.

• EEF1A1 (Triple-Negative Breast Cancer): EEF1A1, a key regulator of peptide chain elongation, was identified as a direct binding partner of a novel Penicillide-derived compound (compound 2) using DARTS and CETSA assays. This compound induces apoptosis, triggers cell cycle arrest, and modulates cancer stem cell properties. Network pharmacology analysis identified RPL27A and RPLP0 as downstream effectors; compound 2 suppresses their expression at the translational level, thereby inhibiting tumor cell invasion and migration.

• CD44v6 (Pancreatic Ductal Adenocarcinoma): Frequently overexpressed in PDAC, CD44v6 is being evaluated as a radiopharmaceutical target using [¹⁷⁷Lu]Lu-AKIR001. Tumor uptake exceeded 100 %IA/g in vivo, and complete remissions were observed in PDAC xenograft models following administration of 12 MBq (40% complete remission) or 4 MBq combined with paclitaxel (14% complete remission), suggesting potential synergistic benefit with combination therapy.

• EZH2 / NRF1 Axis (Multiple Cancers): While EZH2 inhibitors are established, only a small proportion of cancer patients derive benefit. NRF1 (nuclear respiratory factor 1) was identified as the gene most strongly correlated with EZH2 expression; NRF1 directly binds the EZH2 promoter and upregulates its activity. Cancer cells co-expressing active NRF1 and EZH2 show significantly greater sensitivity to EZH2 inhibitors (GSK343 and tazemetostat), positioning combined NRF1/EZH2 expression as a potential predictive biomarker for patient selection.

• SRPK2 (Multiple Cancers): SRPK2 promotes cancer development through its canonical role in alternative splicing and involvement in diverse cellular signaling pathways. Elevated SRPK2 expression across multiple human malignancies consistently correlates with poor clinical outcomes. SRPK2 inhibition has demonstrated antitumor and antimetastatic effects, supporting its designation as both a promising therapeutic target and potential tumor biomarker.

• EGFR / Neoschaftoside (Lung Cancer): EGFR remains a critical regulator of oncogenic cascades including MAPK, PI3K/AKT/mTOR, and JAK-STAT pathways. Neoschaftoside, a bioactive compound derived from Ailanthus altissima, was identified via molecular docking and molecular dynamics simulations as demonstrating strong binding affinity and conformational stability against EGFR. Post-MD analyses, including PCA and DCCM, confirmed restricted global motions and enhanced correlated dynamics upon ligand binding, supporting neoschaftoside as a lead compound for EGFR-targeted therapy.

• miR-218 (Lung Cancer): This microRNA exhibits tumor-suppressive properties and functions as a key regulator of signaling pathways governing proliferation, invasion, metastasis, and apoptosis. Clinical evidence demonstrates an inverse correlation between miR-218 expression levels and tumor aggressiveness, supporting its dual utility as both a diagnostic biomarker and a therapeutic target.

• PSMA and Somatostatin Receptors (Radiopharmaceuticals): [¹⁷⁷Lu]Lu-PSMA-617 (Pluvicto®) has received FDA approval for metastatic castration-resistant prostate cancer, and [¹⁷⁷Lu]Lu-DOTA-TATE (Lutathera®) for neuroendocrine tumors — both exemplifying progress in radiopharmaceutical therapy through optimized pharmacokinetics and biodistribution. Rational combinations with DNA damage response agents such as PARPi or immunotherapies are being explored to further enhance radiopharmaceutical treatment response.